Introgen makes appointment to board
This article was originally published in Scrip
Executive Summary
Introgen Therapeutics, a US biopharmaceutical company focused on the discovery, development and commercialisation of targeted molecular therapies for cancer and other diseases, has elected Dr James Rothman to its board of directors. In September, Dr Rothman, who is renowned for discovering the molecular machinery responsible for transfer of materials among compartments within cells, will relocate his laboratory from Columbia University to Yale University, where he will serve as the Wallace professor of biomedical sciences, chairman of the department of cell biology and founder of the Yale University Center for High-Throughput Cell Biology.